Cooley Advises Intersect ENT on $63 Million Initial Public Offering
Palo Alto – July 31, 2014 – Cooley LLP announced today that it advised Intersect ENT, Inc. on its $63.3 million IPO. Intersect is a commercial drug-device company committed to improving the quality of life for patients with ear, nose and throat conditions. The company now trades on the NASDAQ Global Stock Market under the symbol "XENT."
The Cooley corporate securities team was comprised of partner Matthew Hemington, of counsel Brett White, and associates Seth Gottlieb, Matt Fleming and Daniel Elefant. Critical support for the offering was provided by partner Mark Windfeld-Hansen (tax); partner Renee Deming (compensation and benefits); partner Natasha Leskovsek, special counsel Phil Mitchell and associate Jennifer Shanley (health care and life sciences regulatory).
Thus far in 2014, Cooley has advised on 70 completed public offerings, including 35 completed IPOs.
About Cooley LLP
Cooley's attorneys solve legal issues for entrepreneurs, investors, financial institutions and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and bet-the-company litigation, often where innovation meets the law.
Cooley has more than 750 lawyers across 11 offices in the United States and China.
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.